PANDEMIC INFLUENZA: IS THERE A CORPORATE DUTY TO PREPARE?

被引:0
作者
McMenamin, Joseph P. [1 ]
机构
[1] McGuireWoods LLP, Richmond, VA USA
关键词
CRITICAL-CARE SUMMIT; OSELTAMIVIR TREATMENT; HUMAN INFECTION; JANUARY; 26-27; TASK-FORCE; MANAGEMENT; RESISTANT; IMPACT; DRUGS;
D O I
暂无
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This article considers whether in the wake of an influenza pandemic companies may be exposed to claims of legal liability for failing to provide employees with access to antiviral medications, as the Department of Health and Human Services (HHS) now encourages businesses to do. It begins by describing influenza and influenza pandemics. It then discusses the benefits and limitations of antiviral therapies and the recent creation of antiviral option programs. It concludes by considering whether claims may be brought on the theory that corporate leadership is under a duty to prepare for a pandemic by considering whether to provide access to antiviral protection for employees.
引用
收藏
页码:69 / 100
页数:32
相关论文
共 82 条
[1]  
Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
[2]  
[Anonymous], INDOOR AIR POLLUTION
[3]  
[Anonymous], 2005, Ten things you need to know about pandemic influenza
[4]   Early administration of oral oseltamivir increases the benefits of influenza treatment [J].
Aoki, FY ;
Macleod, MD ;
Paggiaro, P ;
Carewicz, O ;
El Sawy, A ;
Wat, C ;
Griffiths, M ;
Waalberg, E ;
Ward, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :123-129
[5]  
ARNOLD S, 2002, J INFECT DIS, V186, P1582
[6]  
*AV FLU WORK GROUP, 2006, GLOB EC FIN IMP AV F, P3
[7]  
Bainbridge SM, 2008, UCLA LAW REV, V55, P559
[8]  
Balicer RD, 2005, EMERG INFECT DIS, V11, P1280
[9]  
Berry MR, 2004, WASH LAW REV, V79, P1125
[10]  
Bishop CarterG., 2007, MICH ST L REV, V2007, P905